transplant
remain
pioneer
scientif
innov
signific
impact
restor
wellb
patient
benefit
societi
whole
blood
marrow
hematopoiet
stem
cell
becom
accept
instanc
establish
approach
treat
incur
neoplast
diseas
congenit
disord
immun
system
similarli
use
allograft
patient
endstag
organ
diseas
involv
liver
kidney
intestin
heart
lung
provid
possibl
continu
life
potenti
patient
integr
resum
particip
commun
recent
advanc
limb
integu
face
transplant
underscor
substanti
leap
forward
restor
normalci
individu
devast
often
catastroph
physic
encumbr
patient
undergo
solid
organ
transplant
advanc
understand
complex
interplay
within
variou
facet
immun
respons
transplant
allogen
tissu
recipi
immun
system
fail
recogn
self
result
encourag
longterm
outcom
achiev
decod
higher
mammalian
immun
underscor
recent
progress
made
develop
implement
refin
strategi
har
potenti
devast
immun
reject
implant
solid
organ
allograft
antireject
strategi
expect
involv
delic
balanc
favor
preserv
function
allograft
aim
limit
sever
druginduc
suppress
recipi
immun
function
crucial
surveil
variou
neoplast
process
convent
opportunist
infect
similar
albeit
oppos
role
undesir
immun
respons
come
play
patient
undergo
hematopoiet
blood
marrow
stem
cell
transplant
foreign
donor
conflict
aris
aforement
disconnect
immun
recognit
self
versu
nonself
transplant
stem
cell
instal
foreign
effector
immun
cell
recipi
remain
unab
result
graftversushost
diseas
capabl
unleash
potenti
ruinou
system
inflamm
result
irrevers
tissu
damag
death
stem
cell
graft
restor
immun
function
marrow
patient
need
myeloabl
antineoplast
therapi
furthermor
foreign
graftmedi
adapt
cancer
immun
surveil
wide
recogn
pivot
featur
sustain
cancer
remiss
follow
success
allogen
hematopoiet
stem
cell
transplant
featur
stem
cell
graftassist
antitumor
respons
recogn
graftversusleukemia
graftversustumor
effect
donorderiv
adapt
antitumor
immun
import
object
allogen
stem
cell
transplant
especi
patient
hematolog
malign
form
base
donor
lymphocyt
infus
treat
cancer
recurr
posttranspl
period
patient
follow
solid
organ
transplant
recipi
allogen
hsct
antigvhd
therapi
assess
continu
refin
achiev
lowest
possibl
cumul
iatrogen
immun
suppress
requir
prevent
treat
gvhd
wherea
earnest
attempt
made
preserv
recipi
immun
function
risk
convent
opportunist
infect
malign
overwhelm
project
efficaci
feasibl
lifesav
procedur
number
agent
success
use
prevent
treatment
graftversushost
diseas
solid
organ
allograft
reject
sever
immun
dysfunct
instanc
direct
consequ
treatment
agent
commonli
prescrib
combin
drug
regimen
cyclosporin
first
major
breakthrough
regard
subsequ
gener
calcineurin
inhibitor
cni
improv
therapeut
index
although
result
sever
immun
suppress
risk
opportunist
infect
like
cmv
bk
viru
certain
posttranspl
cancer
question
therapeut
feasibl
agent
tacrolimu
especi
patient
low
risk
allograftrel
complic
seriou
infect
due
cytomegaloviru
includ
viremia
endorgan
diseas
bk
viru
viremia
viruria
bk
viru
allograft
nephropathi
risk
potenti
graft
compromis
rare
progress
multifoc
leukoencephalopathi
due
polyomaviru
higher
potenti
opportunist
cancer
kaposi
sarcoma
ebv
lymphoprolif
disord
among
other
wellrecogn
limit
individu
given
tacrolimu
extend
durat
dose
lead
prolong
high
serum
drug
concentr
experi
sirolimu
macrolid
xenobiot
induc
potent
immun
suppress
via
inhibit
mechanist
target
rapamycin
mtor
conserv
threonin
serin
protein
kinas
associ
lower
incid
cmv
infect
solid
organ
transplant
recipi
protect
antivir
effect
mtor
inhibitor
bk
viru
nephropathi
renal
transplant
note
consist
addit
antitumor
properti
mtor
inhibitor
may
favor
influenc
lower
incid
risk
posttranspl
malign
recipi
solid
organ
allograft
especi
profil
indic
low
risk
graft
reject
monoclon
antibodi
tand
bcell
pathway
also
gain
promin
potenti
treatment
option
alemtuzumab
campath
monoclon
antibodi
target
antigen
express
lymphocyt
treatment
campath
result
profound
lymphocyt
deplet
druginduc
immun
suppress
may
last
month
although
maximum
degre
lymphopenia
note
week
therapi
part
hsct
preparatori
condit
regimen
treatment
alemtuzumab
associ
reduc
risk
gvhd
follow
allogen
hematopoiet
stem
cell
transplant
kidney
transplant
recipi
risk
organ
reject
low
patient
given
alemtuzumab
howev
benefit
mainli
observ
patient
low
risk
allograft
reject
trial
underway
aim
explor
regimen
may
spare
cni
tacrolimu
prevent
allograft
reject
human
monoclon
antibodi
rituximab
target
antigen
express
promin
select
b
lymphocyt
form
cornerston
treatment
solid
organ
antibodymedi
renal
allograft
reject
also
consid
standard
care
treatment
posttranspl
bcell
lymphoprolif
disord
system
glucocorticoid
maintain
relev
drug
cocktail
given
prevent
treat
solid
organ
graft
reject
gvhd
sinc
earli
observ
enabl
addit
corticosteroid
success
reduc
cyclosporin
dose
tradit
need
prevent
reject
transplant
allograft
observ
regard
major
breakthrough
forg
path
preserv
transplant
organ
without
seriou
lifethreaten
cni
toxic
detail
discuss
regard
immunosuppress
agent
prevent
treatment
allograft
reject
provid
chapter
throughout
book
keen
understand
patient
underli
immun
defect
knowledg
cornerston
essenti
optim
infect
risk
stratif
assess
need
prevent
preemptiv
empir
antimicrobi
therapi
inform
serv
imper
establish
meaning
patientcent
manag
infect
prevent
paradigm
tabl
provid
outlin
relationship
underli
immun
defect
suscept
particular
group
pathogen
also
import
note
combin
unrel
immun
defect
may
overlap
furthermor
patient
may
present
multipl
infect
concurr
sequenti
close
proxim
primari
infect
episod
varieti
convent
opportunist
microorgan
extens
exposur
hospit
environ
pose
risk
transplant
recipi
acquir
infect
may
respond
convent
antimicrobi
drug
recent
interest
explor
potenti
influenc
perturb
reorgan
host
microbi
flora
microbiota
result
extens
exposur
healthcar
environ
broadspectrum
antimicrobi
drug
among
factor
yield
greater
insight
field
larg
underappreci
decad
alter
orointestin
microbiota
propos
limit
observ
studi
influenc
risk
acquir
infect
recurr
previous
resolv
infect
suboptimum
respons
antimicrobi
therapi
importantli
longterm
viabil
transplant
allograft
possibl
noninfecti
complic
potenti
relationship
alter
host
microbiota
current
investig
import
approach
assess
transplant
patient
lend
understand
knowledg
tempor
relationship
risk
infect
may
occur
variou
clinic
phase
transplant
procedur
tabl
past
two
decad
preval
nonalbican
invas
candidiasi
seen
excess
candida
albican
infect
emerg
invas
diseas
due
candida
auri
limit
suscept
current
use
antifung
drug
challeng
b
certain
transplant
unit
across
usa
seen
high
level
vre
colon
subsequ
risk
invas
diseas
infect
often
surrog
reflect
host
highrisk
statu
c
increas
report
echinocandin
resist
among
clinic
isol
c
glabrata
alarm
trend
becom
promin
futur
among
con
group
bacteria
emerg
recent
describ
highli
virul
staphylococcu
lugdunensi
caus
tissuedestruct
infect
similar
aureu
emphasi
necrot
difficulttotreat
endocard
e
candida
krusei
intrins
nonsuscept
fluconazol
extent
itraconazol
yeast
uniformli
suscept
broadspectrum
triazol
voriconazol
posaconazol
isavuconazonium
sulfat
f
aspergillu
terreu
clinic
relev
aspergillu
speci
exhibit
variabl
degre
resist
amphotericin
b
therebi
increas
probabl
failur
amphotericinbas
therapi
g
candida
parapsilosi
c
guilliermondii
demonstr
less
inher
vitro
suscept
echinocandin
altern
antifung
agent
suggest
treat
infect
h
noncandida
noncryptococc
yeast
rare
caus
fungemia
seen
mainli
patient
sever
immun
dysfunct
chronic
lung
diseas
fusarium
spp
infect
increasingli
attribut
foodrel
intestin
tract
colon
invas
diseas
period
sever
immun
suppress
profound
prolong
neutropenia
especi
patient
extens
orointestin
mucos
disrupt
filament
fungal
pathogen
food
aspergillu
mucor
spp
rare
organ
link
food
food
product
includ
lichtheimia
curvularia
phoma
trichoderma
alternaria
acremonium
paecilomyc
penicillium
achaetomium
amesia
botryotrichum
chaetomium
dichotomopilu
microascu
scopulariopsi
wallemia
mucor
circinelloid
isol
yogurt
sampl
presum
caus
ill
consum
strongyloid
stercorali
may
lead
seriou
lifethreaten
hyperinfect
syndrom
patient
mark
cellular
immun
defect
follow
allogen
allograft
transplant
albeit
remain
rare
complic
patient
undergo
transplant
even
endem
region
strain
human
coronaviru
may
caus
potenti
seriou
lower
respiratori
tract
diseas
immunocompromis
host
n
l
donovani
l
infantum
may
lead
seriou
viscer
leishmaniasi
patient
profound
cellular
immun
defect
l
donovani
seen
africa
asia
novel
outbreak
stain
coronaviru
observ
caus
seriou
ill
immunosuppress
patient
diabet
mellitu
ischem
heart
diseas
endstag
kidney
diseas
p
l
infantum
seen
africa
europ
mediterranean
central
south
america
q
system
extrapulmonari
infect
includ
viral
enceph
along
viral
pneumon
allogen
stem
cell
transplant
recipi
note
caus
devast
lifethreaten
ill
r
incid
campylobact
diseas
aid
patient
higher
gener
popul
patient
humor
cellular
immun
defect
consid
suscept
import
recogn
seriou
sequela
guillainbarr
syndrom
reactiv
arthriti
may
follow
acut
infect
episod
small
group
patient
vzv
rare
associ
system
dissemin
patient
humor
immun
defect
even
mix
immun
dysfunct
emerg
global
spread
communityacquir
methicillinresist
aureu
made
empir
use
antistaphylococc
penicillin
obsolet
c
catheterrel
bloodstream
infect
extens
healthcar
environ
exposur
hospitalacquir
pathogen
persist
mucos
orointestin
cutan
hyperacut
acut
gvhd
acceler
iatrogen
immun
suppress
includ
need
highdos
corticosteroid
salient
factor
promot
invas
bacteri
infect
period
pretranspl
colon
due
vre
mrsa
mdr
gnb
includ
mrd
pseudomona
esblproduc
enterobacteriacea
foodborn
fungi
fusarium
spp
especi
transplant
unit
locat
certain
geograph
area
thought
promot
infect
due
pathogen
hyposplen
hsct
late
complic
commonli
attribut
lateonset
acut
gvhd
frequent
note
patient
chronic
gvhd
howev
import
recogn
number
allogen
hsct
recipi
without
clinic
diagnosi
gvhd
may
function
hyposplen
risk
sever
system
infect
due
encapsul
bacteria
e
indwel
prosthet
devic
includ
intravascular
access
cathet
surgic
drain
implant
prosthesi
heart
valv
joint
biliari
bronchial
urinari
tract
stent
variou
implant
surgic
devic
promot
infect
due
con
candida
spp
commonli
colon
skin
genitourinari
orointestin
tract
f
listeria
bacteremia
mening
rare
complic
patient
receiv
tmpsmx
prophylaxi
pcp
incid
bacteri
mening
higher
hsct
recipi
compar
person
without
hsct
expect
patient
undergo
allograft
stem
cell
transplant
signific
higher
risk
compar
undergo
autolog
hsct
vs
per
patient
per
year
hsct
recipi
streptococcu
pneumonia
common
pathogen
associ
bacteri
mening
neisseria
meningitidi
streptococcu
miti
listeriosi
may
rare
seen
g
increas
frequenc
multidrugresist
strain
fluorin
quinolon
region
high
preval
extendedspectrum
betalactamas
produc
gnb
includ
carbapenemresist
enterobacteriacea
serious
curtail
treatment
option
infect
enterobacteriacea
includ
salmonella
spp
escherichia
coli
yersinia
pesti
klebsiella
spp
shigella
proteu
enterobact
serratia
citrobact
h
cn
nocardiosi
difficult
distinguish
brain
toxoplasmosi
tuberculosi
aspergillosi
neurotrop
clear
hyalin
black
mold
infect
cn
lymphoma
nonfer
gramneg
includ
pseudomona
aeruginosa
burkholderia
cepacia
stenotrophomona
maltophilia
acinetobact
baumannii
acinetobact
spp
alcaligen
achromobact
spp
emerg
case
sphingomona
paucimobili
inher
acquir
drug
resist
major
concern
select
effect
empir
therapi
pathogen
group
may
either
lack
drug
target
site
produc
extendedspectrum
hydrolyz
enzym
aginst
varieti
commonli
use
antimicrobi
bacteria
may
also
exhibit
phenotyp
reduc
express
outer
membran
porin
andor
heighten
express
efflux
pump
among
mechan
antimicrobi
drug
resist
j
orointestin
mucos
increas
risk
cdad
exposur
broadspectrum
antimicrobi
possibl
antineoplast
chemotherapyinduc
alter
host
intestin
protect
anaerob
microbiota
standard
provid
prophylaxi
hsv
vzv
preparatori
condit
regimen
continu
earli
posthsct
period
prophylaxi
may
extend
patient
acut
gvhd
cancer
recurr
patient
undergo
highrisk
transplant
procedur
primari
secondari
allograft
compromis
highgrad
viremia
dna
analysi
associ
central
nervou
system
cn
dysfunct
although
viral
interstitialalveolar
pneumon
uncommon
diseas
attribut
infect
follow
allogen
hsct
may
also
present
limbic
enceph
subcort
tempor
lobe
seizur
activ
present
memori
loss
insomnia
febril
partial
complet
myelosuppress
andor
skin
rash
alert
physician
regard
potenti
treatabl
caus
secondari
stem
cell
allograft
loss
viral
gastroduoden
coliti
pericard
clinic
manifest
attribut
infect
vulner
popul
associ
posthsct
viremia
delay
monocyt
platelet
engraft
increas
platelet
transfus
requir
risk
highgrad
gvhd
allcaus
mortal
need
evalu
earli
cmv
lowgrad
viremia
observ
use
ultrasensit
nucleic
assay
within
week
highrisk
allogen
stem
cell
graft
transplant
u
incid
adenoviru
diseas
rang
high
highrisk
pediatr
allogen
hsct
recipi
patient
undergo
tcelldeplet
stem
cell
graft
acut
graftversushost
diseas
also
increas
risk
sever
lifethreaten
adenoviru
dissemin
diseas
wellrecogn
complic
patient
persist
peripher
blood
lymphocyt
count
cellsmm
infect
involv
respiratori
viral
pneumon
gastrointestin
coliti
includ
hemorrhag
coliti
tract
hepat
patient
may
present
posttranspl
hemorrhag
cystiti
adenoviru
dissemin
repres
sever
underli
immun
defect
seen
patient
endorgan
viral
diseas
except
patient
adenoviru
cystiti
dissemin
adenovir
diseas
seldom
observ
john
cunningham
viru
jcv
associ
progress
multifoc
leukoencephalopathi
pml
uncommon
diseas
patient
undergo
allogen
hsct
report
israel
patient
jcv
reactiv
persist
viremia
receiv
myeloabl
nonmyeloabl
pretranspl
condit
pml
diagnos
two
patient
persist
jcv
viremia
day
hsct
advanc
age
signific
predictor
jcv
reactiv
allogen
hsct
recipi
persist
viral
reactiv
die
identifi
highrisk
patient
persist
jcv
reactiv
especi
increment
level
viremia
may
benefit
reduc
druginduc
immun
suppress
prevent
jcv
leukoencephalopathi
pml
continu
remain
devast
albeit
rare
posttranspl
infecti
complic
artesun
antimalari
drug
show
potent
ex
vivo
activ
howev
clinic
respons
artesun
hsct
recipi
jcvpml
encourag
ac
candidemia
seen
patient
sever
preengraft
neutropenia
absolut
neutrophil
count
cellmicrolit
extend
longer
day
increas
nonalbican
candida
spp
mainli
due
c
glabrata
although
patient
follow
hsct
also
risk
c
krusei
infect
emerg
echinocandin
resist
among
clinic
c
glabrata
isol
concern
patient
c
parapsilosi
infect
recommend
use
antifung
drug
echinocandin
class
emerg
mdr
candida
auri
infect
transplant
popul
make
select
empir
antiyeast
therapi
challeng
ad
genet
suscept
ia
includ
mutat
dcsign
among
well
recogn
risk
factor
highrisk
allogen
hsct
cmv
respiratori
viru
infect
posit
aspergillu
pcr
recent
note
presenc
three
aforement
factor
gener
probabl
develop
ia
patient
risk
factor
probabl
ia
compar
patient
four
risk
factor
ae
cmv
reactiv
stem
cell
allograft
transplant
increas
risk
ifd
late
transplant
period
unlik
risk
factor
earli
ifd
aml
hr
hla
antigenmismatch
donor
graft
hr
hsct
recipi
lymphoma
hr
cmv
reactiv
hr
sever
neutropenia
hr
consid
promin
risk
factor
lateonset
ifd
patient
pretranspl
igg
respons
aspergillu
protein
indic
signific
fungal
colon
ongo
subclin
aspergillu
infect
preparatori
condit
regimen
commenc
need
clinic
valid
evalu
hsct
recipi
comprehens
cancer
center
show
increas
incid
ia
remain
high
decad
author
also
report
increas
frequenc
nonaspergillu
mold
fusarium
spp
mucormycosi
late
nonaspergillu
mold
promin
patient
undergo
multipl
transplant
case
mucormycosi
seen
late
transplant
period
especi
patient
chronic
gvhd
patient
undergo
nonmyeloabl
hsct
presenc
sever
acut
gvhd
chronic
extens
gvhd
cmv
infect
promin
risk
factor
ifd
af
invas
aspergillosi
complic
seen
patient
delay
week
recoveri
peripher
blood
granulocyt
count
patient
receiv
highdos
system
corticosteroid
also
increas
risk
aspergillu
fumigatu
remain
preval
mold
caus
invas
human
diseas
includ
patient
undergo
hsct
infect
caus
scedosporium
fusarium
spp
occasion
seen
hematopoiet
stem
cell
allograft
recipi
commonli
present
period
sever
prolong
neutropenia
ag
routin
blood
cultur
low
sensit
diagnosi
fungemia
carbohydr
biomark
emerg
use
laboratori
test
diagnosi
invas
yeast
mold
diseas
furthermor
may
use
monitor
respons
system
antifung
therapi
infect
relaps
ah
posthsct
recoveri
antigenspecif
lymphocytemedi
immun
respons
cmv
candida
albican
regard
critic
earli
late
transplant
period
patient
develop
antigenspecif
tcell
respons
earli
transplant
period
deriv
clone
donor
recipi
stem
cell
origin
reconstitut
immun
respons
via
antigenspecif
lymphocyt
recipi
origin
weaken
patient
gvhd
incid
ic
year
nonmyeloabl
myeloabl
transplant
condit
lower
ia
echinocandin
nonsuscept
candida
spp
infect
recent
recogn
emerg
challeng
provid
care
highli
vulner
patient
ai
pcp
seriou
oi
transplant
patient
sever
cellular
immun
defect
routin
antipcp
prophylaxi
breakthrough
infect
rare
although
patient
receiv
aerosol
pentamidin
atyp
upper
lung
pcp
may
occasion
occur
aj
invas
zygomycosi
mucormycosi
may
occur
disproport
frequent
patient
voriconazol
prophylaxi
sinuorbit
invas
mold
diseas
transplant
patient
overal
preval
less
among
invas
fungal
infect
ak
nearli
half
patient
dissemin
fusariosi
evid
fungemia
close
may
exhibit
multipl
papular
skin
lesion
necrot
center
indistinguish
ecthyma
gangrenosum
due
staphylococcu
aureu
dissemin
pseudomona
spp
infect
al
dematiac
melanin
pigment
mold
associ
chronic
local
infect
preval
certain
geograph
region
transplant
patient
dissemin
infect
may
occur
neurotrop
import
featur
infect
treatment
older
antifung
drug
amphotericin
b
earli
gener
triazolebas
compound
associ
high
rate
treatment
failur
cumul
incid
cn
infect
follow
hsct
within
first
day
within
month
year
follow
transplant
significantli
high
risk
cn
infect
year
cbt
vs
match
relat
hsct
import
note
purpos
risk
stratif
cn
fungal
viral
infect
promin
wherea
toxoplasmosi
bacteri
infect
seen
patient
aspergillosi
common
follow
cryptococcu
neoforman
cn
infect
transplant
popul
associ
high
mortal
low
overal
surviv
patient
extens
tcell
immun
defect
strongyloid
stercorali
may
caus
acceler
autoinfect
hyperinfect
pulmonari
syndrom
patient
almost
alway
fatal
screen
serolog
test
presenc
strongyloidiasi
enzymelink
immunosorb
assay
allogen
hsct
may
fals
neg
stool
ova
parasit
examin
absenc
acceler
autoinfect
pretranspl
also
riddl
low
sensit
aq
american
trypanosomiasi
caus
trypanosoma
cruzi
need
assess
patient
plan
undergo
allograft
transplant
procedur
endem
region
ar
leishmania
transmit
bite
certain
speci
sand
fli
present
cutan
common
viscer
uncommon
sever
diseas
pretranspl
evalu
includ
serolog
test
prior
exposur
parasit
appropri
patient
high
risk
prior
exposur
suppur
necrosi
lung
ischem
necrosi
ie
pulmonari
infarct
also
consid
tissu
invas
mold
lung
diseas
may
also
compar
radiograph
present
fig
ct
scan
lung
without
intraven
contrast
show
treeinbud
appear
due
pulmonari
mycobacterium
avium
complex
diseas
mostli
involv
right
lung
demonstr
multipl
area
centrilobular
nodul
linear
branch
pattern
endobronchi
tuberculosi
may
present
radiograph
find
wherein
patient
acut
develop
treeinbud
infiltr
bacteri
viral
cmv
etiolog
may
also
entertain
import
note
bronchiectasi
promin
radiograph
present
mycobacterium
avium
complex
infect
patient
undergo
transplant
rare
carcinomat
endarter
due
breast
gastric
cancer
bronchovascular
interstiti
infiltr
due
lymphoma
leukemia
sarcoidosi
may
similar
present
scedosporium
lung
diseas
pulmonari
fusariosi
may
occassion
nodular
peribrochovascular
distribut
addit
risk
infect
often
seen
asplen
patient
function
hyposplen
patient
chronic
gvhd
increas
risk
system
fungal
diseas
like
invas
aspergillosi
herp
viru
reactiv
herald
cmv
viremia
addit
encapsul
bacteria
outlin
tabl
may
also
includ
risk
profil
evalu
patient
patient
receiv
treatment
acut
gvhd
allogen
hsct
heighten
risk
invas
aspergillosi
infect
due
filament
mold
unlik
first
risk
period
invas
mold
diseas
allogen
stem
cell
recipi
coincid
period
preengraft
sever
neutropenia
patient
acut
chronic
gvhd
seldom
neutropen
tabl
illustr
salient
featur
infect
risk
associ
type
stem
cell
graft
pretranspl
condit
preparatori
regimen
drug
commonli
use
prevent
gvhd
cord
blood
stem
cell
regard
major
breakthrough
sourc
yield
steadi
suppli
hematopoiet
stem
cell
especi
among
patient
difficult
find
immunolog
hlamatch
compat
hematopoiet
stem
cell
graft
cord
blood
stem
cell
limit
number
nucleat
cell
adequ
children
adult
fig
ct
scan
lung
without
intraven
contrast
show
bilater
nodular
zygomycosi
patient
follow
allogen
hsct
receiv
voriconazol
prophylaxi
right
lung
nodul
central
caviti
radiograph
exclud
caus
nodular
pneumonia
invas
pulmonari
aspergillosi
fusarium
spp
mold
lung
diseas
among
bacteria
nocardia
spp
concern
allograft
transplant
recipi
radiograph
present
primari
lung
lymphoma
may
similar
present
rare
patient
relaps
acut
leukemia
post
hsct
period
may
present
atyp
pulmonari
infiltr
dens
consolid
involv
lower
lobe
patient
gvhd
develop
infect
due
dematiac
mold
follow
allogen
hsct
differenti
diagnosi
necrot
bacteri
clear
hyalin
black
melanin
pigment
mold
infect
also
consid
along
multifoc
pulmonari
nocardiosi
due
larger
bodi
surfac
area
transplant
less
optimum
number
stem
cell
complic
posttranspl
period
issu
inadequ
delay
neutrophil
engraft
peripher
blood
cell
count
recoveri
precari
graft
stabil
similar
recipi
tcelldeplet
graft
higher
risk
infect
associ
sever
prolong
neutropenia
observ
gvhd
tabl
variou
strategi
explor
assuag
limit
includ
transplant
cord
blood
graft
one
donor
ex
vivo
expans
singl
donor
cord
blood
graft
increas
yield
nucleat
cell
review
cord
blood
transplant
comprehens
cancer
center
houston
texa
infect
incid
rate
ratio
total
infect
episod
per
day
risk
surviv
cbt
time
higher
adult
patient
compar
children
import
note
risk
infect
even
greater
three
time
higher
adult
neutropenia
time
higher
patient
gvhd
compar
children
undergo
cbt
procedur
consid
essenti
creat
comprehens
infect
assess
strategi
take
account
recogn
local
issu
particular
transplant
unit
uniqu
patient
popul
approach
requir
cogniz
exist
influenc
may
promot
risk
infect
includ
local
region
infect
trend
pattern
pathogen
preval
drug
suscept
profil
continu
vigil
regard
emerg
pathogen
everchang
infect
risk
profil
advanc
transplant
procedur
druginduc
immun
suppress
paramount
import
provid
care
highli
vulner
transplant
popul
varieti
noninfecti
condit
may
clinic
radiograph
emul
infecti
process
among
noninfecti
maladi
involv
skin
lung
great
imit
present
difficult
clinic
distinguish
infect
cellul
pneumonia
two
chapter
volum
dedic
provid
indepth
discuss
topic
approach
establish
correct
diagnosi
opportunist
infect
base
maxim
uncertain
obtain
tissu
sampl
dilig
adjud
central
tenet
establish
accur
diagnosi
immunolog
vulner
patient
procliv
atyp
diseas
present
complic
ascertain
correct
time
diagnosi
inaccur
diagnosi
old
dispens
serolog
culturebas
system
may
lead
inappropri
ineffect
treatment
worsen
patient
morbid
risk
complic
death
therefor
focus
yet
comprehens
differenti
diagnos
encompass
etiolog
infect
noninfecti
caus
may
mimic
infecti
process
includ
limit
drug
toxic
de
novo
malign
post
transplant
cancer
recurr
typic
atyp
present
lymphoprolif
disord
immuneinflammatori
diseas
like
gvhd
tissu
infiltr
process
solid
allograft
reject
among
other
may
greatli
improv
guidanc
optim
manag
approach
patient
undergo
lifesav
stem
cell
solid
organ
allograft
transplant
stem
cell
sourc
preparatori
condit
regimen
gvhd
prophylaxi
immun
defect
infect
allogen
vs
autolog
graft
allograft
recipi
exhibit
gradual
recoveri
cellular
adapt
immun
function
preengraft
neutropenia
longer
day
increas
risk
invas
candidiasi
imd
innat
immun
function
aid
cellular
acellular
antimicrobi
defens
recov
earli
transplant
especi
patient
undergo
convent
autolog
nonmyeloabl
hsct
herald
granulocyt
engraft
posttranspl
resolut
neutropenia
ifd
heighten
risk
coincid
peak
incid
acut
chronic
gvhd
complement
antimicrobi
peptid
reconstitut
earli
transplant
sever
respiratori
viral
infect
also
problemat
patient
given
system
corticosteroid
immunosuppress
therapi
gvhd
patient
persist
sever
thrombocytopenia
may
follow
highrisk
allogen
stem
cell
recipi
may
continu
exhibit
reduc
host
defens
due
suboptimum
thrombinreleas
antimicrobi
peptid
platelet
includ
platelet
factor
rant
connect
tissueactiv
peptid
platelet
basic
protein
thymosin
fibrinopeptid
b
fibrinopeptid
impact
deplet
plateletassist
immun
defens
potenti
higher
suscept
infect
hsct
recipi
sever
thrombocytopenia
certain
cmv
less
commonli
dissemin
adenoviru
encount
patient
profound
defect
anticmv
antivir
pathogenspecif
effector
cellular
immun
respons
myeloid
plasmacytoid
dendrit
cell
recov
within
day
allogen
hsct
pretranspl
level
unless
patient
develop
acut
gvhd
case
recoveri
significantli
delay
howev
may
take
year
longer
achiev
normal
function
dc
cell
popul
undergo
allogen
stem
cell
transplant
plasmacytoid
dc
import
regul
mainten
immun
toler
defens
virus
myeloid
dc
serv
apc
pivot
elicit
pathogendirect
cellular
adapt
immun
respons
recoveri
nk
cell
patient
undergo
allogen
hsct
occur
usual
day
transplant
innat
immun
effector
cell
directli
lyse
virusinfect
cell
provid
antineoplast
immun
surveil
nk
cell
import
readili
avail
albeit
transient
sourc
gmcsf
chemokin
rant
play
critic
role
adapt
immun
modul
notabl
lack
qualit
nk
cell
recoveri
patient
tcelldeplet
transplant
may
render
less
effect
prolong
period
mismatch
unrel
donor
stem
cell
allograft
transplant
carri
signific
risk
seriou
lifethreaten
infect
seen
late
month
posttranspl
period
cmv
infect
acut
gvhd
contribut
significantli
toward
risk
late
fatal
infect
includ
pneumonia
sepsi
central
nervou
system
infect
dissemin
varicella
slow
reconstitut
adapt
cellular
helper
cytotox
immun
delay
patient
requir
treatment
acut
gvhd
ia
month
transplant
associ
chronic
gvhd
cmv
diseas
humor
immun
respons
may
fulli
recov
patient
chronic
gvhd
fusarium
spp
ifd
threefold
higher
patient
undergo
hlamismatch
vs
hlamatch
hsct
case
occur
median
day
transplant
trimod
distribut
similar
ia
coincid
preengraft
neutropenia
day
year
transplant
correspond
incid
acut
chronic
gvhd
respect
bone
marrow
sourc
stem
cell
treatment
highdos
corticosteroid
delay
recoveri
function
tcellbas
immun
month
longer
transplant
persist
neutropenia
similar
seen
case
dissemin
scedosporium
spp
infect
invas
mold
diseas
allogen
hsct
promin
prognost
death
patient
fusariosi
also
recogn
subclin
cmv
reactiv
patient
ganciclovir
prophylaxi
preemptiv
therapi
appear
potent
stimul
tcell
function
transplant
seriou
infect
includ
ebvptld
dissemin
dissemin
adenoviru
infect
peripher
blood
stem
cell
graft
vs
bone
marrow
stem
cell
rate
sever
proven
infect
follow
stem
cell
engraft
higher
patient
bone
marrow
sct
given
compar
undergo
transplant
pbsc
allograft
blood
stem
cell
graft
higher
lymphocyt
subset
count
part
account
fewer
infecti
complic
posttranspl
period
hlamatch
relateddonor
peripher
blood
stem
cell
appear
lend
protect
ia
earli
transplant
period
compar
undergo
similar
bone
marrow
stem
cell
allograft
transplant
late
transplant
immun
suppress
due
chronic
gvhd
may
occur
greatest
benefit
pbsc
vs
bmsc
note
risk
profil
ifd
wherea
bacteri
infect
benefit
intermedi
least
viral
infect
continu
adult
patient
requir
higher
number
total
nucleat
cell
progenitor
often
present
cord
blood
unit
yield
instabl
allograft
even
success
engraft
mitig
limit
especi
adult
strategi
expand
select
subpopul
stem
cell
within
cord
blood
unit
transplant
multiunit
cb
current
explor
cbt
recipi
higher
incid
sever
bacteri
infect
within
day
transplant
howev
year
cbt
risk
sever
bacteri
infect
compar
patient
undergo
bmt
peripher
blood
allogen
hsct
slower
restitut
tcell
pathogenspecif
cellular
immun
respons
cord
blood
tcell
predominantli
exhibit
suboptimum
tcell
prolifer
ifngamma
product
respons
insult
exposur
foreign
antigen
inher
cellular
dysfunct
cb
graft
appear
reflect
defect
signal
transduct
pathway
cmv
infect
andor
presenc
acut
gvhd
significantli
increas
risk
ia
furthermor
tcell
dysfunct
may
also
aris
promin
treg
popul
cb
potent
suppressor
function
compar
moder
treg
popul
adult
donorderiv
stem
cell
graft
ifd
similar
bacteri
infect
seen
within
day
transplant
hypogammaglobulinemia
bcell
dysfunct
may
occur
patient
chronic
gvhd
nearli
half
earli
fungal
infect
may
note
within
first
day
cbt
risk
graft
reject
sever
acut
gvhd
compar
observ
follow
pbsc
bmsc
transplant
despit
high
degre
hla
antigen
donorrecipi
dispar
adult
patient
undergo
cbt
cmv
varicella
zoster
viru
infect
day
follow
cbt
mostli
seen
patient
chronic
gvhd
graftversusleukemialymphoma
effect
cbt
recipi
also
compar
convent
stem
cell
graft
transplant
patient
recov
peripher
blood
lymphocyt
count
follow
success
cbt
engraft
significantli
low
risk
seriou
system
infect
tcelldeplet
stem
cell
graft
higher
risk
graft
reject
may
issu
patient
higher
risk
infect
prolong
preengraft
neutropenia
slower
reconstitut
cellular
humor
immun
risk
factor
ia
note
allogen
hsct
recipi
includ
tcelldeplet
stem
cell
graft
treatment
system
corticosteroid
gvhd
presenc
sever
lymphocytopenia
neutropenia
cell
recov
rapidli
wherea
helper
tcell
b
lymphocyt
recoveri
remain
significantli
stunt
year
longer
lymphocytedeplet
stem
cell
graft
transplant
cmv
infect
endorgan
diseas
lrti
due
rtv
recogn
import
predictor
ia
ifd
postengraft
period
natur
killer
cell
also
make
earli
sustain
recoveri
transplant
despit
tcelldeplet
pbsc
graft
higher
number
mononuclear
cell
granulocytemacrophag
unit
compar
bm
graft
recoveri
b
lymphocyt
tcell
subpopul
dissimilar
either
group
patient
also
exhibit
subnorm
level
prime
tcell
repertoir
promin
lymphocyt
popul
stem
cell
graft
compos
tcell
prime
lymphocyt
includ
activ
helper
tcell
import
sustain
sourc
ifngamma
critic
cytokin
target
intracellular
neutral
variou
pathogen
hypogammaglobulinemia
issu
patient
undergo
tcelldeplet
vs
convent
stem
cell
transplant
nearli
half
cmv
viremia
note
day
transplant
cmv
infect
expect
mostli
encount
resolut
neutropenia
substanti
reduc
incid
gvhd
especi
sever
grade
iiiiv
acut
gvhd
close
ifi
late
transplant
infect
diagnos
day
nmt
associ
unaccept
high
mortal
presenc
gvhd
treatment
system
corticosteroid
significantli
increas
risk
ifd
patient
late
transplant
immun
suppress
due
chronic
gvhd
may
occur
bcell
dysfunct
present
often
repres
defici
immunoglobulin
subclass
rather
sever
hypogammaglobulinemia
risk
ia
nmt
appear
increas
time
wellund
within
year
hsct
overal
risk
increas
around
year
close
year
transplant
patient
gvhd
involv
intestin
tract
show
signific
risk
ia
nmt
transplant
recipi
includ
undergo
autolog
sct
bcell
hyporespons
clinic
demonstr
reduc
immunogen
convent
vaccin
respons
protein
conjug
vaccin
tend
superior
compar
respons
elicit
pure
polysaccharid
complex
sugar
immunogen
superior
conjug
vaccin
construct
requir
restitut
cellular
immun
respons
function
antigen
present
process
gvhd
treatment
daclizumab
enhanc
risk
ia
daclizumab
human
monoclon
antibodi
bind
alpha
subunit
tcell
receptor
result
sever
iatrogen
druginduc
cellular
immun
suppress
adult
rapid
engraft
nmt
becom
full
donor
tcell
chimera
within
month
transplant
contrast
children
quantit
bcell
recoveri
adult
usual
delay
year
hsct
interest
immun
reconstitut
occur
faster
children
undergo
nmt
exhibit
extend
durat
mix
hematopoiet
chimer
wherea
adult
reconstitut
gradual
despit
rapid
donor
stem
cell
engraft
tcell
chimer
continu
stem
cell
sourc
preparatori
condit
regimen
gvhd
prophylaxi
immun
defect
infect
total
bodi
irradi
chemotherapyinduc
mucos
radiat
exposur
highli
activ
antineoplast
drug
kill
rapidli
prolifer
cancer
cell
rapidli
divid
normal
orointestin
epitheli
cell
also
sustain
unintend
damag
may
clinic
present
patient
sever
potenti
lifethreaten
mucos
patient
sever
mucos
especi
mucos
ulcer
threefold
higher
risk
streptococc
bacteremia
compar
without
ulcer
mucos
follow
hsct
patient
presenc
oral
ulcer
significantli
increas
length
hospit
nearli
week
variou
strategi
includ
recombin
human
keratinocyt
growth
factor
among
other
explor
mitig
seriou
debilit
complic
commonli
seen
earli
posttranspl
period
similarli
presenc
orointestin
mucos
associ
risk
neutropen
enterocol
typhliti
cdad
initi
phase
chemotherapyinduc
stomatotox
infiltr
tissu
inflammatori
cell
vascular
congest
follow
epitheli
cell
damag
result
ulcer
risk
bacteri
less
often
yeast
invas
result
system
infect
patient
surviv
phase
expect
make
full
recoveri
risk
fungemia
due
candida
spp
may
also
increas
patient
diverg
cytokin
respons
play
import
role
risk
sever
durat
mucos
host
genet
predisposit
patient
intestin
vre
colon
mucos
disrupt
heighten
risk
system
invas
risk
vre
bloodstream
infect
later
tbi
complic
month
treatment
mostli
noninfecti
includ
restrict
lung
diseas
alter
pulmonari
diffus
capac
pulmonari
complic
statist
higher
patient
gvhd
underw
highdos
mv
vs
mv
energi
beam
radiat
therapi
ocular
complic
note
nearli
patient
longterm
followup
includ
cataract
dri
eye
syndrom
wherea
kerat
seldom
seen
antithymocyt
globulin
atg
polyclon
human
antilymphocyt
globulin
result
multifacet
immunomodul
shown
reduc
incid
solid
organ
graft
reject
gvhd
follow
allogen
hsct
incid
ebvrel
complic
twice
high
patient
undergo
nonhlamatch
vs
hlamatch
allograft
stem
cell
transplant
risk
significantli
higher
patient
given
antithymocyt
globulin
versu
treatment
given
hsct
recipi
persist
ebv
reactiv
develop
ebvrel
ptld
suggest
target
surveil
atg
vivo
deplet
proinflammatori
cytotox
tcell
peripher
blood
via
complementdepend
cell
lysi
peripher
lymphoid
tissu
tcell
deplet
occur
via
cell
activ
apoptosi
febril
ill
cmv
infect
hematolog
abnorm
known
complic
patient
treat
atg
atg
downregul
express
receptor
express
activ
lymphocyt
therebi
interrupt
import
signal
cell
prolifer
modul
key
cell
surfac
molecul
integrin
intercellular
adhes
molecul
facilit
regul
lymphocyt
interact
endothelium
chemotaxi
effect
interfer
stromal
cellderiv
lymphocyt
migrat
atg
induc
apoptosi
bcell
lineag
promot
expand
function
immunosuppress
regulatori
tcell
abbrevi
gvhd
graftversushost
diseas
cmv
cytomegaloviru
dc
dendrit
cell
nk
natur
killer
pml
jc
virusassoci
progress
multifoc
leukoencephalopathi
ptld
epsteinbarr
virusassoci
bcell
lymphoprolif
disord
ifd
invas
fungal
diseas
cdad
clostridium
difficileassoci
diarrhea
cbt
cord
blood
stem
cell
transplant
ia
invas
aspergillosi
ic
invas
candidiasi
treg
regulatori
tcell
hsct
hematopoiet
stem
cell
transplant
imd
invas
mold
diseas
human
herp
viru
rant
regul
activ
normal
tcell
express
secret
apc
antigenpres
cell
interferon
gamma
ntm
nonmyeloabl
transplant
nst
gmcsf
granulocytemacrophag
colonystimul
factor
cb
cord
blood
stem
cell
bmsc
bone
marrow
stem
cell
pbsc
peripher
blood
stem
cell
lrti
lower
respiratori
tract
infect
sct
stem
cell
transplant
hla
human
leukocyt
antigen
